<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="ml">
   <head>
      <meta http-equiv="Content-Type" content="application/xhtml+xml; charset=utf-8"/>
      <title>Stem_cell_based_drug</title>
      <meta name="dc:identifier" content="AUTO-UID-0239"/>
      <meta name="dt:version" content="2.0.0.0 Beta"/>
      <meta name="dc:title" content="Stem_cell_based_drug"/>
      <meta name="dc:creator" content="Vikram"/>
      <meta name="dc:date" content="2018-05-08"/>
      <meta name="dc:publisher" content="IIIT"/>
      <meta name="dc:identifier" content="AUTO-UID-0239"/>
      <meta name="dc:language" content="en"/>
      <link rel="stylesheet" type="text/css" href="default.css"/>
   </head>
   <body>
      <h1 class="title" id="dtb1">
         <a href="speechgen0001.smil#text1">Stem_cell_based_drug</a>
      </h1>
      <div class="docauthor" id="dtb2">
         <a href="speechgen0001.smil#text2">Vikram</a>
      </div>
      <div class="level1">
         <span class="page-normal" id="page0001">
            <a href="speechgen0001.smil#text3">1</a>
         </span>
         <h1 id="dtb3">
            <a href="speechgen0002.smil#text4">Empty Heading</a>
         </h1>
         <p>
            <span class="sentence" id="dtb4">
               <a href="speechgen0002.smil#text5">
India now has its ﬁrst ever indigenously
developed biological drug containing
human stem cells.

</a>
            </span>
            <span class="sentence" id="dtb5">
               <a href="speechgen0002.smil#text6">A Bengaluru—based stem cell company,
Stempeutics Research has received regulatory


</a>
            </span>
         </p>
         <span class="page-normal" id="page0002">
            <a href="speechgen0002.smil#text7">2</a>
         </span>
         <p id="dtb6">
            <a href="speechgen0002.smil#text8">
    
approval for ‘limited marketing’ of its
product for the treatment of Critical Limb
Ischemia (CLI) due to Buerger’s disease
— the ﬁrst stem cell based biologics to be
approved by the Drugs Controller General
of India (DCGI).



        </a>
         </p>
         <span class="page-normal" id="page0003">
            <a href="speechgen0002.smil#text9">3</a>
         </span>
         <p>
            <span class="sentence" id="dtb7">
               <a href="speechgen0002.smil#text10">
    
CLI is a progressive form of peripheral
arterial disease which blocks the arteries in
the legs resulting in reduced blood ﬂow. </a>
            </span>
            <span class="sentence" id="dtb8">
               <a href="speechgen0002.smil#text11">This
leads to severe pain and ulcers or necrosis
which ﬁnally may require amputation. </a>
            </span>
            <span class="sentence" id="dtb9">
               <a href="speechgen0002.smil#text12">CLI
affects 3.4 million patients in India and

        </a>
            </span>
         </p>
         <span class="page-normal" id="page0004">
            <a href="speechgen0002.smil#text13">4</a>
         </span>
         <p>
            <span class="sentence" id="dtb10">
               <a href="speechgen0002.smil#text14">
    
approximately 2 per 10,000 persons in the
European Community and USA.

</a>
            </span>
            <span class="sentence" id="dtb11">
               <a href="speechgen0002.smil#text15">“Now there is hope for these patients,”
says Balu Manohar, the company’s CEO.
</a>
            </span>
            <span class="sentence" id="dtb12">
               <a href="speechgen0002.smil#text16">Its ﬂagship product “stempeucel” —
patented in the US, Japan, China and
Malaysia — is derived from allogeneic
pooled mesenchymal stromal cells (MSC),
extracted from the bone marrow of adult
voluntary donors.

</a>
            </span>
            <span class="sentence" id="dtb13">
               <a href="speechgen0002.smil#text17">“This is the ﬁrst allogeneic MSC
transplantation study in India,” Manohar
said adding that the pooling technology
developed is also novel and has been
patented.

</a>
            </span>
            <span class="sentence" id="dtb14">
               <a href="speechgen0002.smil#text18">The DCGI approval for “stempeucel” is
based on clinical data generated in phase-l
and phase—Z trials on 90 subjects With
Buerger’s disease. </a>
            </span>
            <span class="sentence" id="dtb15">
               <a href="speechgen0002.smil#text19">“In both Phase studies,

        </a>
            </span>
         </p>
         <span class="page-normal" id="page0005">
            <a href="speechgen0002.smil#text20">5</a>
         </span>
         <p>
            <span class="sentence" id="dtb16">
               <a href="speechgen0002.smil#text21">
    
signiﬁcant improvement in blood ﬂow is
observed compared to placebo or control
group of patient,” Manohar said.

</a>
            </span>
            <span class="sentence" id="dtb17">
               <a href="speechgen0002.smil#text22">Although it is too early to say
if Stempeucel would improve amputation —
free survival in these patients, the clinical
data suggests that disease progression has
been halted and clinical improvement
observed in several parameters, he said.
</a>
            </span>
            <span class="sentence" id="dtb18">
               <a href="speechgen0002.smil#text23">“This improvement is consistent for a period
of 6 months follow up of these patients.”

</a>
            </span>
            <span class="sentence" id="dtb19">
               <a href="speechgen0002.smil#text24">Under DCGI’S limited approval,
Stempeutics can manufacture and sell its
product to 200 patients on a cost recovery
basis (limited to Rupees 150000 or $2200)
per patient and submit the data to DCGI’S
ofﬁce before seeking full marketing
authorization. </a>
            </span>
            <span class="sentence" id="dtb20">
               <a href="speechgen0002.smil#text25">“They have given us a time
window of two years,” Manohar said. </a>
            </span>
            <span class="sentence" id="dtb21">
               <a href="speechgen0002.smil#text26">“Our


</a>
            </span>
         </p>
         <span class="page-normal" id="page0006">
            <a href="speechgen0002.smil#text27">6</a>
         </span>
         <p>
            <span class="sentence" id="dtb22">
               <a href="speechgen0002.smil#text28">
    
goal is to complete the study on 200 patients
and seek full marketing authorisation by the
end of next year.”

</a>
            </span>
            <span class="sentence" id="dtb23">
               <a href="speechgen0002.smil#text29">“This is a huge win for patients, for
Stempeutics, and for the ﬁeld of MSC
therapy,” Jeffrey Karp, Associate Professor
of Medicine at Harvard Medical School
who is also in the company’s advisory board
told Nature India. </a>
            </span>
            <span class="sentence" id="dtb24">
               <a href="speechgen0002.smil#text30">“Also, we must commend
the Indian regulators for promoting
regenerative medicine for major unmet
medical needs.”

</a>
            </span>
            <span class="sentence" id="dtb25">
               <a href="speechgen0002.smil#text31">Stempeutics is working to globalise its
product, which has already been granted
the Advanced Therapy Medicinal Product
and Orphan Drug Designation status by
European Medicinal Agency. </a>
            </span>
            <span class="sentence" id="dtb26">
               <a href="speechgen0002.smil#text32">“This will help
us fast-track commercialisation in Europe,”
said Manohar.

        </a>
            </span>
         </p>
      </div>
   </body>
</html>